Mandate

Vinge advises Hansa Medical in connection with directed share issue

October 24, 2016

The board of directors of Hansa Medical proposes a capital raising through a directed share issue, whereby the company will receive approximately SEK 185 million.

The share issue is directed to selected international specialist investors as well as Swedish institutional and strategic investors. The issue proceeds will primarily be used to finance the development process of the drug candidate IdeS up to an application for market authorization of IdeS for treatment in connection with kidney transplantation. The share issue is fully subscribed for in accordance with agreements executed with the selected investors. Shareholders representing approximately 45 percent of Hansa Medical’s shares and votes have undertaken to vote in favor of the board’s proposal for the share issue at an extraordinary general meeting.

Hansa Medical is a biopharmaceutical company focused on novel immunomodulatory enzymes. The company’s shares are admitted to trading on Nasdaq Stockholm.

Vinge’s team consists of Dain Hård Nevonen, Erik Sjöman and Nils Fredrik Dehlin.

Related

Vinge advises Baseload Capital in connection with an investment from Google

Vinge has advised Baseload Capital Holding AB in connection with securing an investment from Google.
April 16, 2025

Vinge advises Acrinova in connection with the sale of properties

Vinge advises Acrinova AB (publ) in connection with its sale of properties with an underlying property value of SEK 1.4 billion.
April 15, 2025

Vinge has advised Visa in connection with its investment in Mynt AB

Vinge has advised Visa in connection with its investment in the Swedish fintech company Mynt AB ("Mynt"). The investment, which is part of Mynt's announced Series B funding round, underscores Visa's commitment to supporting innovative fintech solutions and improving payment experiences for businesses across Europe.
April 14, 2025